OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Gastroenterology & Hepatology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
GORD: pain, PPIs, and preciseness	1682
Viral hepatitis: time for action	604
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30	552
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy	492
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	471
Lucky: Learning to Live Again	452
EASL Congress 2024	366
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study	361
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	343
Treatment withdrawal in Crohn's disease: slowly becoming clearer	298
Research in Brief	274
Trends in alcohol-specific deaths in the UK and industry responses	274
Immune checkpoint inhibitors in colorectal cancer: dream and reality	256
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	238
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	233
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	232
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	229
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	220
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	208
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	208
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	193
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	193
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	193
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	190
Global multi-stakeholder endorsement of the MAFLD definition	182

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	179
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	175
ACG 2024	174
Long-term VEDOKIDS results: implications for practice and research	168
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?	161
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p	152
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	151
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	145
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study	144
Availability of point-of-care HBV tests in resource-limited settings	143
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply	138
Management of portal vein thrombosis in cirrhosis	137
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study	134
Idiopathic gastroparesis consensus misses the patient's voice	133
Research in Brief	127
Uptick of food allergies in recent years—real or epiphenomenon?	123
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	119
Has the time come for a systematic top-down approach in Crohn's disease?	119
Resmetirom for NASH: balancing promise and prudence	118
Addressing the rise of early-onset colorectal cancer	116
Local and systemic therapy in liver cancer: the quest for synergy	115
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	114
The potential of ctDNA in locoregional therapies for colorectal cancer	112
All roads lead to the gut–brain microbiome network	108
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)	108
Water and sanitation for all	106
Bringing organ preservation closer for selected patients with rectal cancer	106
Rare cause of dysphagia in a young woman	104
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	104
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis	103
Sex and gender in inflammatory bowel disease outcomes and research	102
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	100
Hypovolaemic phlebotomy for hepatic resection	98
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	98
The Year My Life Went Down the Toilet	97
Lifting the minority tax in gastroenterology and hepatology	97
Management of malignant bowel obstruction – Authors' reply	94
A women-focused matrix mentorship programme in gastroenterology	94
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	93
Urgent action needed to achieve viral hepatitis elimination	91
Research in Brief	86
The growth of faecal microbiota transplantation in the UK: time for a registry?	86
Dangerous Medicine	86
Practicalities accessing precision medicine in biliary tract cancer	84
Research in Brief	82
Another arrow in the NASH quiver?	79
Robotic versus laparoscopic surgery for middle and low rectal cancer	77
18th Congress of the European Crohn's and Colitis Organisation	76
An unusual complication after a variceal glue injection	76
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	75

CEND-1: a game changer for pancreatic cancer chemotherapy?	75
Britta Siegmund: answering the big questions in IBD	75
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist	74
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities	73
Shitbag: the story of a diagnosis	73
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED	73
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de	70
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	70
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	69
Redefining palliation in malignant gastric outlet obstruction	69
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial	68
Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial	67
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines	66
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	64
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	63
Primary biliary cholangitis and the narrowing gap towards optimal disease control	61
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	61
Managing inflammatory bowel disease: what to do when the best is unaffordable?	60
Research in brief	60
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	60
Primary intestinal lymphangiectasia	59
Management of portal vein thrombosis in cirrhosis – Authors' reply	59
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	59
Bowel cancer prevention: are we missing an opportunity?	59
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines	58
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	58
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	56
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	56
Lessons learned from the BOSS trial	56
Research in Brief	55
COP27 Climate Change Conference: urgent action needed for Africa and the world	55
The world is failing on hunger	55
Compensation advised for UK victims of contaminated blood scandal	55
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	54
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	54
The problem of antimicrobial resistance in chronic liver disease	54
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	54
Alcohol and health: time for Europe to sober up	54
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	53
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	52
Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations	52
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	51
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	51
The intestinal barrier: a pivotal role in health, inflammation, and cancer	51
Increasing burden of colorectal cancer in China	51
Diet or optimised medical therapy for people with irritable bowel syndrome	50
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	50
Does filgotinib work for Crohn's disease?	50
Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials	49
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	49
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	49
Gastroenterology training in Africa: an assessment of curriculum and perception	49
Correction to Lancet Gastroenterol Hepatol 2025; 10: 715–25	48
Watch and wait for rectal cancer: towards data-informed surveillance	48
Lessons and open questions in borderline resectable pancreatic cancer	48
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	47
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis	46
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	45
Standardising early liver transplantation for severe alcohol-related hepatitis	45
World Hepatitis Day 2025: elimination at a critical juncture	45
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	45
The costs of inadequate toilet coverage in the Philippines	44
Spleen stiffness in portal hypertension algorithms: the next advance	44
Research in Brief	44
DEI in gastroenterology and hepatology	44
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	44
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial	43
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	43
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	42
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	42
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	42
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	42
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	41
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	41
Combination locoregional and systemic therapies in hepatocellular carcinoma	41
Oncological safety of laparoscopic surgery for low rectal cancer	40
Time for a treat all approach for hepatitis B	40
More is not always better for novel hepatitis B therapies	39
Endoscopic interventions for stricturing Crohn's disease	38
Research in Brief	38

Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?	38
Inequities in alcohol-related harm in the Philippines	37
The International Liver Congress 2022	37
Research in Brief	37
A coordinated multipronged attack: integrated care is the future for gastroenterology	37
Inclusion of patients with isolated ulcerative proctitis in clinical trials	36
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	35
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	34
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial	34
Accelerating point-of-care HCV viral load testing	34
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	34
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	33
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	33
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	33
Launch of the International Living Donor Liver Transplantation Outcomes Registry	32
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	32
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	32
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	31
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from	31
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	30
Chronic Boom	30
No accident: the UK infected blood scandal	30
The Liver Meeting 2023	30
Tackling obesity: drugs are only part of the solution	29
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	29
Haematopoietic stem-cell transplantation in Crohn's disease	29
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	28
Local ablation in pancreatic cancer: some answers and more questions	28
17th Congress of ECCO	27
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	27
Comparison of trends in early-onset colorectal cancer in North America and Europe	27
Refining the faecal incontinence core outcome set – Authors' reply	27
Retina and liver fibrosis screening for patients with type 2 diabetes	27
Oral faecal microbiota transplantation in ulcerative colitis	27
Psychological therapies in inflammatory bowel disease	27
Vedolizumab in paediatric IBD: a huge step forward but not there yet	26
Terlipressin for hepatorenal syndrome: opportunities and challenges	26
Challenging stigma around alcohol misuse	26
Lessons from a trial of colesevelam for bile acid diarrhoea	25
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	25
A new chapter in the campaign to eliminate viral hepatitis?	24
Séverine Vermeire: advancing patient-centred research in IBD	24
The Liver Meeting 2025	24
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	24
The urgent need to end hepatitis B stigma and discrimination	24
Research in Brief	24
Cultural competence in the delivery of nutrition and symptom care in irritable bowel syndrome	23
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	23
A call for advocacy and patient voice to eliminate hepatitis B virus infection	23
Robotic pancreatoduodenectomy: preparing for the future	22
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	22
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	22
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	21
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	21
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	21
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial	21
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	21
Diet or optimised medical therapy for people with irritable bowel syndrome	20
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	20
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	20
Research in Brief	20
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	19
NAFLD prevalence and severity in overweight and obese populations	19
An important step towards the long-term treatment of eosinophilic oesophagitis	19
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	19
Financing viral hepatitis: catalysing action for impact	19
Non-coeliac gluten sensitivity: from Salerno to Rome	19
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	19
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	19
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	19
Research in Brief	18
Septic arthritis: a presentation of Crohn's disease	18
Variceal embolisation plus TIPS for variceal bleeding	18
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	17
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	17
Are all post-ESWL pancreatitis events clinically significant?	17
Research in Brief	16
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	16
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	16
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	16
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial	16
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	16
Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial	15
Weighing the benefits of screening for early-onset colorectal cancer	15
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health	14
Targeting type 2 immune responses to treat eosinophilic gastritis	14
Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver disease	14
Targeting the EGFR signalling pathway in metastatic colorectal cancer	14
A path to global cirrhosis health equity	14
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-infe	14
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial – Authors' reply	14
Proximal serrated polyp detection rate and interval post-colonoscopy colorectal cancer risk – Authors' reply	14
Ranking treatments in the network meta-analysis should consider the certainty of evidence	13
The first new drug for progressive familial intrahepatic cholestasis	13
ACG 2021	13